A RANDOMIZED PHASE II STUDY OF PEMBROLIZUMAB (KEYTRUDA®) PLUS STEREOTACTIC RE-IRRADIATION VERSUS SBRT ALONE FOR LOCOREGIONALLY RECURRENT OR SECOND PRIMARY HEAD AND NECK CARCINOMA

May 09, 2019
https://clinicaltrials.gov/ct2/show/NCT03546582
Cancer - Head and Neck
Principal Investigator: Eleanor M Walker, MD

 PEMBROLIZUMAB, STEREOTACTIC RE-IRRADIATION, SBRT, HEAD AND NECK CARCINOMA

Accepting Participants